VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
Titel:
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
Auteur:
Kelley, R.K. Yau, T. Cheng, A.-L. Kaseb, A. Qin, S. Zhu, A.X. Chan, S. Sukeepaisarnjaroen, W. Breder, V. Verset, G. Gane, E. Borbath, I. Gomez Rangel, J.D. Merle, P. Benzaghou, F.M. Banerjee, K. Hazra, S. Fawcett, J. Rimassa, L.